Abstract: Peptides having, as constitutive amino acids, (1) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue and 5 leucine residues, and having a 3-hydroxydecanoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof; (2) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 3 valine residues, and 5 leucine residues, and having a 3-hydroxydecanoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof; or (3) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue and 5 leucine residues, and having a 3-hydroxydodec-5-enoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof. The peptides have an antiviral activity. A strain capable of producing the above peptides and belonging to a new species of genus Pseudomonas.

Abstract: Sulfofucosylacylglycerol derivatives represented by General Formula (1): where R101 represents an acyl residue of a higher fatty acid and R102 represents a hydrogen atom or an acyl residue of a higher fatty acid. The derivatives represented by General formula (1) are useful as a DNA polymerase inhibitor and an anticancer agent.

Abstract: A method of designing a molecular structure of an inhibitor of a target enzyme by analyzing, in the tertiary structure of a first enzyme, a geometric configuration formed by amino acids to which an inhibitor on the first enzyme is to bind. The method comprises (1) a step of determining the amino acid group of the first enzyme to which the inhibitor is to bind, (2) a step of determining the geometric configuration of the amino acid group of the step (1), (3) a step of searching for an amino acid group having a geometric configuration similar to that of the step (2), in the target enzyme, and (4) a step of searching weather or not (i) the amino acids constituting the amino acid group are present at the surface of the target enzyme, and (ii) the amino acids have been conserved in different species by comparison with an enzyme derived from an organism of different types from the organism from which the target enzyme is derived.

Abstract: According to the present invention, a cushion-action applying implement comprising a gutter-like receiver, a plate spring in which a flexing portion is inserted into the gutter-like portion, the flexing portion is provided in its both sides with embedded portions in series, and an angle formed by the embedded portions is V or nearly horizontal, a switching shaft provided with a cam for pushing the flexing portion of the plate spring to change the angle formed by the embedded portions and in which an engaging portion for rotation is provided on the end thereof, a bearing of the switching shaft fixedly mounted on both ends of the gutter-like receiver, and a drive means for rotating the switching shaft is embedded in the flexing portion of the footwear bottom body, whereby the switching shaft is rotated to simply switch to the state of presence or the state of absence of cushioning.

Abstract: A method for treating a cancer. The cancer excluding an adenocarcinoma and being epithelioma, glioma, sarcoma, melanoma, lymphoma or leukemia; or the cancer is an adenocarcinoma cancer excluding colon cancer, lung cancer and gastric cancer.

Abstract: An anticancer drug includes a compound represented by Formula (1): where R101 represents an acyl moiety of a saturated higher fatty acid, and R102 represents a hydrogen atom or an acyl moiety of a saturated higher fatty acid, and/or a pharmaceutically acceptable salt thereof.

Abstract: An anticancer drug includes a compound represented by Formula (1): where R101 represents an acyl moiety of a saturated higher fatty acid, and R102 represents a hydrogen atom or an acyl moiety of a saturated higher fatty acid, and/or a pharmaceutically acceptable salt thereof.

Abstract: A method for immunosuppression in a subject comprising administering to the subject in need thereof, a pharmaceutically effective amount of at least one sulfoquinovosylacylglycerol derivative represented by General formula (1-1): wherein R101 represents an acyl residue of a higher fatty acid, and R102 represents a hydrogen atom or an acyl residue of a higher fatty acid; and a pharmaceutically acceptable salt thereof. Of the sulfoquinovosylacylglycerol derivatives, &bgr;-sulfoquinovosylacylglycerols are novel compounds. The present invention also relates to pharmaceutical composition comprising a pharmaceutically effective amount of the &bgr;-sulfoquinovosylacylglycerols and/or its pharmaceutically acceptable salt; and a pharmaceutically acceptable excipient. The pharmaceutical composition may be used as an immunosuppressive agent, anticancer agent and DNA polymerase &agr; inhibitor.

Abstract: The present invention provides a footwear bottom capable of simply switching to the state of presence or the state of absence of cushioning.

Abstract: An anticancer drug includes a compound represented by Formula (1): 1

Abstract: 1-O-(2-propenyl)-6-O-sulfonylpyranoside represented by the formula wherein R1, R2 and R3 each independently represents an alkyl or substituted silyl group, and R4 represents an alkylsulfonyl or arylsulfonyl group.

Abstract: 1-O-(2-propenyl)-6-deoxy-6-carbonylthiopyranoside represented by the formula wherein R1, R2 and R3 each independently represents an alkyl or a substituted silyl group, and R5 represents a hydrogen atom, or an alkyl or aryl group.

Abstract: A method for immunosuppression in a subject comprising administering to the subject in need thereof, a pharmaceutically effective amount of at least one sulfoquinovosylacylglycerol derivative represented by General formula (1-1): 1

Abstract: Novel sulfofucosylacylglycerol derivatives represented by General Formula (1): 1

Abstract: A medicament containing at least one compound selected from the group consisting of compounds represented by General formula (1): 1

Abstract: Novel sulforhamnosylacylglycerol derivatives represented by General Formula (1): 1

Abstract: An embedded isolation region and a process for forming the same on the substrate made of silicon. The isolation region(s) is constituted of a silicon nitride region, a silicon oxide region and, if required, a channel stop region in this order in the upper surface of the substrate to the deep inside of the substrate. The isolation region(s) is formed by an ion implantation technique using a mask made of an oxide film, followed by oxidation and removal of at least an upper substrate region on the upper side of the silicon nitride region. As compared with the formation of a conventional trench type region(s), even isolation regions with different sizes or an isolation region having portions with different sizes can be formed without a fear of entailing an uneven surface, and the development of crystal defects can be mitigated without an increase in the number of steps, while, even in a trench filled with poly-Si, at the same time some adverse effect of the remaining poly-Si on element regions can be avoided.

Abstract: A method for producing a substance highly containing high content of maltose therein, by saccharifying a liquefied starch with amylase produced by streptomyces at the same time with or after treatment with .beta.-amylase.